Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early intravesical Botox for bladder and renal protection in infants with spina bifida
NL-OMON40616Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of botulinum toxin type A in neurogenic bladder, spina bifida (SB) and myelomeningocele (MMC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Bladder end filling pressure. Started Oct 2014; status: active, not recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic bladderspina bifida (SB)myelomeningocele (MMC)
Beyond the preview
Go deeper on NL-OMON40616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40616.